TFF PHARMACEUTICALS, INC. (TFFP): Price and Financial Metrics


TFF PHARMACEUTICALS, INC. (TFFP): $5.76

0.11 (+1.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TFFP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TFFP POWR Grades


  • Stability is the dimension where TFFP ranks best; there it ranks ahead of 31.77% of US stocks.
  • TFFP's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • TFFP ranks lowest in Momentum; there it ranks in the 4th percentile.

TFFP Stock Summary

  • For TFFP, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • With a price/sales ratio of 1,859.12, TFF Pharmaceuticals Inc has a higher such ratio than 99.76% of stocks in our set.
  • As for revenue growth, note that TFFP's revenue has grown 236.94% over the past 12 months; that beats the revenue growth of 96.53% of US companies in our set.
  • Stocks that are quantitatively similar to TFFP, based on their financial statements, market capitalization, and price volatility, are VNRX, LXRX, VXRT, OTIC, and ASND.
  • TFFP's SEC filings can be seen here. And to visit TFF Pharmaceuticals Inc's official web site, go to www.tffpharma.com.

TFFP Valuation Summary

  • In comparison to the median Healthcare stock, TFFP's EV/EBIT ratio is 124.57% lower, now standing at -7.2.
  • Over the past 23 months, TFFP's price/sales ratio has gone NA NA.
  • Over the past 23 months, TFFP's price/earnings ratio has gone up 10.4.

Below are key valuation metrics over time for TFFP.

Stock Date P/S P/B P/E EV/EBIT
TFFP 2021-08-31 8411.5 3.9 -9.4 -7.2
TFFP 2021-08-30 8430.8 3.9 -9.4 -7.2
TFFP 2021-08-27 8342.3 3.9 -9.3 -7.1
TFFP 2021-08-26 7953.8 3.7 -8.9 -6.6
TFFP 2021-08-25 8107.7 3.8 -9.1 -6.8
TFFP 2021-08-24 8303.8 3.9 -9.3 -7.0

TFFP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TFFP has a Quality Grade of D, ranking ahead of 8.49% of graded US stocks.
  • TFFP's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TFFP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -13.217
2021-03-31 0.001 1 -26.319
2020-12-31 0.000 NA -46.985
2020-09-30 0.000 NA -310.219
2020-06-30 0.000 NA 41.705
2019-12-31 0.000 NA 70.796

TFFP Price Target

For more insight on analysts targets of TFFP, see our TFFP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.00 Average Broker Recommendation 1.5 (Moderate Buy)

TFFP Stock Price Chart Interactive Chart >

Price chart for TFFP

TFFP Price/Volume Stats

Current price $5.76 52-week high $10.70
Prev. close $5.65 52-week low $3.60
Day low $5.56 Volume 29,500
Day high $5.96 Avg. volume 136,338
50-day MA $5.35 Dividend yield N/A
200-day MA $6.68 Market Cap 146.15M

TFF PHARMACEUTICALS, INC. (TFFP) Company Bio


TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. The Company develops powder and molecule drugs for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals serves clients in the State of Texas.


TFFP Latest News Stream


Event/Time News Detail
Loading, please wait...

TFFP Latest Social Stream


Loading social stream, please wait...

View Full TFFP Social Stream

Latest TFFP News From Around the Web

Below are the latest news stories about TFF Pharmaceuticals Inc that investors may wish to consider to help them evaluate TFFP as an investment opportunity.

TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant

Preclinical studies show that TFF Pharmaceuticals Inc's (NASDAQ: TFFP) inhaled niclosamide product candidate inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2. More specifically, nirmatrelvir and molnupiravir showed complete inhibition of the Omicron variant at 2.5 μM. In the studies announced today by TFF Pharmaceuticals, inhaled niclosamide demonstrated complete inhibition of Omicron at only 1μM. These studies also confirm the previous findings, which validated th

Yahoo | February 24, 2022

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose Expecting to Complete Phase 1 Safety and Pharmacokinetic Data of Inhaled Niclosamide by End of 1Q’22 AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film

Yahoo | February 24, 2022

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple Variants AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it ha

Yahoo | January 27, 2022

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP): Are Analysts Optimistic?

We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the...

Yahoo | January 12, 2022

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic

Yahoo | December 21, 2021

Read More 'TFFP' Stories Here

TFFP Price Returns

1-mo -0.17%
3-mo -17.24%
6-mo -33.64%
1-year -40.12%
3-year N/A
5-year N/A
YTD -35.06%
2021 -38.06%
2020 167.66%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5229 seconds.